Literature DB >> 2061435

Vibrio vulnificus septicemia in Korea: clinical and epidemiologic findings in seventy patients.

S D Park1, H S Shon, N J Joh.   

Abstract

We studied the clinical characteristics and the epidemiology of primary septicemia associated with Vibrio vulnificus in 70 patients. All patients came from the western and southern coastal areas of Korea. Most cases (96%) occurred during the summer months, in men (96%), and in persons 40 or more years of age (90%). The illness of 46 patients (66%) began with septicemia, often within 2 days of the consumption of raw seafood. Forty-seven patients (67%) had preexisting hepatic disease, and 49 (70%) had a history of alcoholism. Of the 70 patients, 45 (79%) died. The cutaneous lesions that were present on admission in 64 patients (91%) appeared on the legs in 51 of the cases. V. vulnificus was isolated from the blood of 65 patients tested and from the skin lesions of 51 of 55 patients tested. The histopathologic findings differed according to the clinical stage of lesions. Because V. vulnificus septicemia is a highly fatal disease, persons with liver disease or alcoholism should avoid eating or handling raw seafood.

Entities:  

Mesh:

Year:  1991        PMID: 2061435     DOI: 10.1016/0190-9622(91)70059-b

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  25 in total

1.  Pulmonary damage by Vibrio vulnificus cytolysin.

Authors:  J W Park; S N Ma; E S Song; C H Song; M R Chae; B H Park; R W Rho; S D Park; H R Kim
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Thermal-death times of opaque and translucent morphotypes of Vibrio vulnificus.

Authors:  C M Kim; K C Jeong; J H Rhee; S H Choi
Journal:  Appl Environ Microbiol       Date:  1997-08       Impact factor: 4.792

3.  Does Vibrio vulnificus present a health threat to Canadians?

Authors:  S Stavric; B Buchanan
Journal:  Can J Infect Dis       Date:  1997-09

4.  The pyrH gene of Vibrio vulnificus is an essential in vivo survival factor.

Authors:  Shee Eun Lee; Soo Young Kim; Choon Mee Kim; Mi-Kwang Kim; Young Ran Kim; Kwangjoon Jeong; Hwa-Ja Ryu; Youn Suhk Lee; Sun Sik Chung; Hyon E Choy; Joon Haeng Rhee
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

Review 5.  Winner of the Theodore E. Woodward Clinical Award. Monster of the Chesapeake Bay--Vibrio vulnificus.

Authors:  F M Calia
Journal:  Trans Am Clin Climatol Assoc       Date:  1995

6.  In vitro antimicrobial susceptibility of Vibrio vulnificus isolated in Taiwan.

Authors:  P R Hsueh; J C Chang; S C Chang; S W Ho; W C Hsieh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

7.  A calcium-calmodulin antagonist blocks experimental Vibrio vulnificus cytolysin-induced lethality in an experimental mouse model.

Authors:  Young-Rae Lee; Kwang-Hyun Park; Zhao-Zhen Lin; Young-Jong Kho; Jin-Woo Park; Hye-Won Rho; Bon-Sun Koo; Hyung-Rho Kim; Eun-Kyung Song; Hong-Nu Yu; Myung-Kwan Han; Seung-Ok Lee; Eun-Chung Jhee; Jong-Suk Kim
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.

Authors:  Y C Chuang; W C Ko; S T Wang; J W Liu; C F Kuo; J J Wu; K Y Huang
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Comparative genome analysis of Vibrio vulnificus, a marine pathogen.

Authors:  Chung-Yung Chen; Keh-Ming Wu; Yo-Cheng Chang; Chuan-Hsiung Chang; Hui-Chi Tsai; Tsai-Lien Liao; Yen-Ming Liu; Hsiang-Ju Chen; Arthur Bo-Ting Shen; Jian-Chiuan Li; Teh-Li Su; Chung-Ping Shao; Chung-Te Lee; Lien-I Hor; Shih-Feng Tsai
Journal:  Genome Res       Date:  2003-12       Impact factor: 9.043

10.  Primary Shewanella algae bacteremia mimicking Vibrio septicemia.

Authors:  Dae Seong Myung; Young-Sun Jung; Seung-Ji Kang; Young A Song; Kyung-Hwa Park; Sook-In Jung; Soo Hyun Kim; Jong-Hee Shin
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.